Confirmation of the suitability and stability of the imatinib mesylate drug product formulation for intravenous administration in the INVENT-COVID clinical trial

Abstract: An isotonic sterile aqueous solution of imatinib mesylate was formulated and then manufactured according to cGMP by KABS Laboratories. A solution pH of 5.0 is optimum for imatinib mesylate solubility and stability and this is maintained by a sodium acetate buffer. The drug product for the clinical study was presented as a sterile solution in a Type 1 clear glass vial with chlorobutyl stopper and seal. Stability studies on the drug product have confirmed an excellent stability profile and these data are presented in Table 1. The drug product specification detailed in this table is consistent with Regulatory Authority requirements for this stage in clinical development. These data support the conclusion that the drug product used in the INVENT-COVID trial was fully compliant with all cGMP and EU Regulatory Authority requirements.

Keywords

imatinib, stability

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average